8-KOther Events

Edwards Lifesciences Corp 8-K Report (Feb 6, 2004)

Filed February 6, 2004For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) has announced the acquisition of Percutaneous Valve Technologies, Inc. (PVT) for a total of up to $155 million in cash. This strategic move aims to integrate PVT's innovative catheter-based technology for aortic heart valve replacement into Edwards' portfolio. The acquisition is expected to result in a significant in-process research and development charge for Edwards in the first quarter of 2004, estimated between $60 million and $90 million ($1.00 to $1.50 per share). Investors should note that while this acquisition represents a potential advancement in cardiac valve replacement technology, the estimated R&D charge is substantial and subject to uncertainties. The additional $30 million contingent on milestones highlights the performance-based nature of part of the deal. Investors should monitor future filings for details on the integration of PVT's technology and its impact on future financial performance and market position.

Key Highlights

  • 1Acquisition of Percutaneous Valve Technologies, Inc. (PVT) for up to $155 million in cash.
  • 2PVT possesses catheter-based (percutaneous) technology for replacing aortic heart valves.
  • 3The deal includes an initial cash payment of $125 million.
  • 4An additional $30 million in cash is payable upon achievement of certain milestones.
  • 5Expected in-process R&D charge of $60 million to $90 million ($1.00 to $1.50 per share) in Q1 2004.
  • 6The acquisition expands Edwards' technological capabilities in minimally invasive cardiac procedures.
  • 7The filing includes forward-looking statements regarding the acquisition's financial impact.

Frequently Asked Questions

Edwards Lifesciences is acquiring Percutaneous Valve Technologies (PVT) to integrate PVT's advanced catheter-based technology for aortic heart valve replacement into its own product offerings. This move aims to enhance Edwards' position in the minimally invasive cardiac device market.

The acquisition has a total potential cost of up to $155 million in cash. Edwards anticipates recognizing a significant in-process research and development (R&D) charge in the first quarter of 2004, estimated to be between $60 million and $90 million, which translates to approximately $1.00 to $1.50 per share. This estimate is subject to uncertainties.

Yes, in addition to the initial $125 million cash payment, Edwards Lifesciences may pay up to an additional $30 million in cash to PVT shareholders upon the achievement of certain predefined milestones. This suggests a component of the deal is tied to the future success and integration of PVT's technology.

The primary risks highlighted include the uncertainty surrounding the actual amount of the in-process R&D charge, which could differ from the current estimate. Additionally, like all forward-looking statements in SEC filings, the actual results of the acquisition and the integration of PVT's technology may differ materially from management's expectations due to various market and operational factors.